Studienübersicht des TORM, Stand 06/2015

Die Studienübersicht kann hier im PDF Format heruntergeladen werden.

KRAS mutiert :: Second line:

Zurück zur Übersicht


NCT01750281 :: HSK :: Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment. (SELECT-2)

The purpose of this study is to treat patients with locally advanced or metastatic NSCLC with a combination therapy of selumetinib and two different doses of docetaxel 75mg/m2 or 60 mg/m2 vs placebo and compare how well each dose affects how their cancer responds. It will also help us to understand the tolerability profile of the different dosing regimens in these patients